{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:22:55Z","timestamp":1761218575340,"version":"build-2065373602"},"reference-count":36,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The concept of One Health is not new; it can be traced back for at least two hundred years [...]<\/jats:p>","DOI":"10.3390\/jcm12082808","type":"journal-article","created":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T02:08:11Z","timestamp":1681265291000},"page":"2808","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["No Boundaries for Toxicology in Clinical Medicine: One Health, One Society and One Planet for All of Us"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7430-6297","authenticated-orcid":false,"given":"Ricardo Jorge","family":"Dinis-Oliveira","sequence":"first","affiliation":[{"name":"TOXRUN\u2014Toxicology Research Unit, University Institute of Health Sciences (IUCS), CESPU, 4585-116 Gandra, Portugal"},{"name":"Department of Public Health and Forensic Sciences, and Medical Education, Faculty of Medicine, University of Porto, 4200-319 Porto, Portugal"},{"name":"UCIBIO-REQUIMTE, Applied Molecular Biosciences Unit, Laboratory of Toxicology, Department of Biological Sciences, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal"},{"name":"MTG Research and Development Lab, 4200-604 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"key":"ref_1","first-page":"1","article-title":"One Health: Its origins and future","volume":"365","author":"Atlas","year":"2013","journal-title":"Curr. Top Microbiol. Immunol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"100086","DOI":"10.1016\/j.onehlt.2019.100086","article-title":"A one health perspective on dairy production and dairy food safety","volume":"7","author":"Garcia","year":"2019","journal-title":"One Health"},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hoelzer, K., Wong, N., Thomas, J., Talkington, K., Jungman, E., and Coukell, A. (2017). Antimicrobial drug use in food-producing animals and associated human health risks: What, and how strong, is the evidence?. BMC Vet. Res., 13.","DOI":"10.1186\/s12917-017-1131-3"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Rabinowitz, P.M., Natterson-Horowitz, B.J., Kahn, L.H., Kock, R., and Pappaioanou, M. (2017). Incorporating one health into medical education. BMC Med. Educ., 17.","DOI":"10.1186\/s12909-017-0883-6"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/ACM.0b013e31827bfbeb","article-title":"Perspective: Environment, biodiversity, and the education of the physician of the future","volume":"88","author":"Balsari","year":"2013","journal-title":"Acad. Med."},{"key":"ref_6","unstructured":"World Health Organization (2023, March 23). Quadripartite Call to Action for One Health for a Safer World. Available online: https:\/\/www.who.int\/news\/item\/27-03-2023-quadripartite-call-to-action-for-one-health-for-a-safer-world."},{"key":"ref_7","first-page":"5","article-title":"Confronting zoonoses through closer collaboration between medicine and veterinary medicine (as \u2018one medicine\u2019)","volume":"43","author":"Kahn","year":"2007","journal-title":"Vet. Ital."},{"key":"ref_8","first-page":"97","article-title":"\u2018One toxicology\u2019, \u2018ecosystem health\u2019 and \u2018one health\u2019","volume":"45","author":"Beasley","year":"2009","journal-title":"Vet. Ital."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s13181-012-0224-4","article-title":"Toxicology and \u201cOne Health\u201d: Opportunities for Multidisciplinary Collaborations","volume":"8","author":"Rumbeiha","year":"2012","journal-title":"J. Med. Toxicol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.NAJ.0000532078.72372.c3","article-title":"The Great London Smog of 1952","volume":"118","author":"Polivka","year":"2018","journal-title":"Am. J. Nurs."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s13181-011-0172-4","article-title":"Toxicology, environmental health, and the \u201cOne Health\u201d concept","volume":"7","author":"Buttke","year":"2011","journal-title":"J. Med. Toxicol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.endeavour.2012.10.003","article-title":"From coal to DDT: The history of the development of the pesticide DDT from synthetic dyes till Silent Spring","volume":"36","author":"Jarman","year":"2012","journal-title":"Endeavour"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2460\/javma.233.2.259","article-title":"Executive summary of the AVMA One Health Initiative Task Force report","volume":"233","author":"King","year":"2008","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/S0140-6736(15)60901-1","article-title":"Safeguarding human health in the Anthropocene epoch: Report of The Rockefeller Foundation-Lancet Commission on planetary health","volume":"386","author":"Whitmee","year":"2015","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Wadsworth, E., Drummond, C., and Deluca, P. (2018). The Dynamic Environment of Crypto Markets: The Lifespan of New Psychoactive Substances (NPS) and Vendors Selling NPS. Brain Sci., 8.","DOI":"10.3390\/brainsci8030046"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Welz, A., Koba, M., Ko\u015bli\u0144ski, P., and Si\u00f3dmiak, J. (2021). Rapid Targeted Method of Detecting Abused Piperazine Designer Drugs. J. Clin. Med., 10.","DOI":"10.3390\/jcm10245813"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Welz, A., Koba, M., Ko\u015bli\u0144ski, P., and Si\u00f3dmiak, J. (2022). Comparison of LC-MS and LC-DAD Methods of Detecting Abused Piperazine Designer Drugs. J. Clin. Med., 11.","DOI":"10.3390\/jcm11071758"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Poyatos, L., Torres, A., Papaseit, E., P\u00e9rez-Ma\u00f1\u00e1, C., Hladun, O., N\u00fa\u00f1ez-Montero, M., de la Rosa, G., Torrens, M., Fuster, D., and Muga, R. (2022). Abuse Potential of Cathinones in Humans: A Systematic Review. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041004"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/psychoactives1010001","article-title":"The Genesis of a New Open-Access Journal Focused on the Latest Scientific Advances in Psychoactive Substances","volume":"1","year":"2022","journal-title":"Psychoactives"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Ni\u017enansk\u00fd, \u013d., Ni\u017enansk\u00e1, \u017d., Kuruc, R., Sz\u00f3r\u00e1dov\u00e1, A., \u0160ikuta, J., and Zummerov\u00e1, A. (2022). Ayahuasca as a Decoction Applied to Human: Analytical Methods, Pharmacology and Potential Toxic Effects. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041147"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Dacosta-S\u00e1nchez, D., D\u00edaz-Batanero, C., Fernandez-Calderon, F., and Lozano, \u00d3.M. (2021). Impact of Cluster B Personality Disorders in Drugs Therapeutic Community Treatment Outcomes: A Study Based on Real World Data. J. Clin. Med., 10.","DOI":"10.3390\/jcm10122572"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jsat.2020.02.005","article-title":"The application of digital health to the assessment and treatment of substance use disorders: The past, current, and future role of the National Drug Abuse Treatment Clinical Trials Network","volume":"112s","author":"Marsch","year":"2020","journal-title":"J. Subst. Abuse Treat"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Magalh\u00e3es, T., Dinis-Oliveira, R.J., and Taveira-Gomes, T. (2022). Digital Health and Big Data Analytics: Implications of Real-World Evidence for Clinicians and Policymakers. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19148364"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1080\/03602532.2019.1620763","article-title":"Pharmacokinetic and pharmacodynamic of bupropion: Integrative overview of relevant clinical and forensic aspects","volume":"51","author":"Costa","year":"2019","journal-title":"Drug Metab. Rev."},{"key":"ref_25","first-page":"6852857","article-title":"Metabolic Profiles of Propofol and Fospropofol: Clinical and Forensic Interpretative Aspects","volume":"2018","year":"2018","journal-title":"Biomed. Res. Int."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jflm.2018.12.005","article-title":"Metabolism and metabolomics of opiates: A long way of forensic implications to unravel","volume":"61","year":"2019","journal-title":"J. Forensic. Leg. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"184","DOI":"10.2174\/1874467211666181010154139","article-title":"Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions","volume":"12","author":"Pereira","year":"2019","journal-title":"Curr. Mol. Pharmacol."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Lobato-Freitas, C., Brito-da-Costa, A.M., Dinis-Oliveira, R.J., Carmo, H., Carvalho, F., Silva, J.P., and Dias-da-Silva, D. (2021). Overview of Synthetic Cannabinoids ADB-FUBINACA and AMB-FUBINACA: Clinical, Analytical, and Forensic Implications. Pharmaceuticals, 14.","DOI":"10.3390\/ph14030186"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1080\/03602532.2018.1448867","article-title":"The synthetic cathinone \u03b1-pyrrolidinovalerophenone (\u03b1-PVP): Pharmacokinetic and pharmacodynamic clinical and forensic aspects","volume":"50","year":"2018","journal-title":"Drug Metab. Rev."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2987","DOI":"10.1007\/s00204-018-2281-1","article-title":"Drugs of abuse from a different toxicological perspective: An updated review of cocaine genotoxicity","volume":"92","author":"Oliveira","year":"2018","journal-title":"Arch. Toxicol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/03602532.2020.1758712","article-title":"Pharmacokinetics and pharmacodynamics of dextromethorphan: Clinical and forensic aspects","volume":"52","author":"Silva","year":"2020","journal-title":"Drug Metab. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/08897077.2019.1700584","article-title":"Pharmacokinetic and pharmacodynamic of the cognitive enhancer modafinil: Relevant clinical and forensic aspects","volume":"41","author":"Sousa","year":"2020","journal-title":"Subst. Abus."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Calvo, A., Alonso, S., Prieto, E., Ascaso-Del-Rio, A., Ortu\u00f1o, J., Fernandez, N., and Portol\u00e9s, A. (2022). Single and Multiple Dose PK-PD Characterization for Carisoprodol. Part I: Pharmacokinetics, Metabolites, and 2C19 Phenotype Influence. Double-Blind, Placebo-Controlled Clinical Trial in Healthy Volunteers. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030858"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Calvo, A., Gonz\u00e1lez-Hidalgo, M., Terleira, A., Fern\u00e1ndez, N., and Portol\u00e9s, A. (2022). Carisoprodol Single and Multiple Dose PK-PD. Part II: Pharmacodynamics Evaluation Method for Central Muscle Relaxants. Double-Blind Placebo-Controlled Clinical Trial in Healthy Volunteers. J. Clin. Med., 11.","DOI":"10.3390\/jcm11041141"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.drugalcdep.2019.05.025","article-title":"Impact of Schedule IV controlled substance classification on carisoprodol utilization in the United States: An interrupted time series analysis","volume":"202","author":"Li","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Vincze, I., Czermann, R., Nagy, Z., Kov\u00e1cs, M., Neely, M., Farkas, R., Kocsis, I., Karvaly, G.B., and Kopitk\u00f3, C. (2022). Assessment of Antibiotic Pharmacokinetics, Molecular Biomarkers and Clinical Status in Critically Ill Adults Diagnosed with Community-Acquired Pneumonia and Receiving Intravenous Piperacillin\/Tazobactam and Hydrocortisone over the First Five Days of Intensive Care: An Observational Study (STROBE Compliant). J. Clin. Med., 11.","DOI":"10.3390\/jcm11144140"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2808\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:13:45Z","timestamp":1760123625000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/8\/2808"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":36,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12082808"],"URL":"https:\/\/doi.org\/10.3390\/jcm12082808","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}